137 | IBRUTINIB ADDED TO MCL TREATMENT HAS STRONG IMPACT ON MRD RESPONSE AND DISEASE KINETICS: RESULTS FROM THE TRIANGLE TRIAL

Mouhamad Khouja(University Hospital Schleswig-Holstein), Christiane Pott(University Hospital Schleswig-Holstein), Simone Ferrero(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), M. Gomes da Silva, Ana Milena Herrera(Instituto de Investigación Biomédica de Salamanca), Susanne Kubetzko(University Children's Hospital Zurich), Eva Hoster(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Paula Gameiro(IPO Porto), Jon Riise(Oslo University Hospital), Britta Kehden(University Hospital Schleswig-Holstein), Ulrich Mey(Kantonsspital Graubünden), Sirpa Leppä(University of Helsinki), Eva Giné(Aristotle University of Thessaloniki), Elisa Genuardi(University of Turin), Jan Walewski(The Maria Sklodowska-Curie National Research Institute of Oncology), Christian Schmidt, Carsten Utoft Niemann(University of Copenhagen), Ofer Shpilberg(Texas Oncology), Vindi Jurinović(Ludwig-Maximilians-Universität München), O. J. H. M. Verhagen(Sanquin), Eva Froňková(Charles University), Martin Hutchings(University of Copenhagen), V. K. Vergote, Marco Ladetto(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Aurora Maria Civita(University of Turin), Marek Trněný(Charles University), M. Dreyling(Ludwig-Maximilians-Universität München), Wolfgang Hiddemann(Christian-Albrechts-Universität zu Kiel), Michael Unterhalt, V.H. van der Velden(Erasmus MC), Christa Homburg(Sanquin), M. Jerkemann(Lund University), Jeanette K. Doorduijn(Erasmus MC Cancer Institute)
Hematological Oncology
June 1, 2025
Cited by 1


Related Papers